I3 PHARMS
SpecialtyI3 PHARMS is a specialty pharmaceutical company focused on Cardiovascular, Infectious Disease.
I3 PHARMS's Key Drugs
I3 PHARMS's core commercial portfolio centers on ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
I3 PHARMS's Recent FDA Approvals
New NDA/BLA approvals for I3 PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
I3 PHARMS's Therapeutic Areas
I3 PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
I3 PHARMS's Top Competitors
I3 PHARMS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
I3 PHARMS Pipeline Snapshot
Active clinical trials for I3 PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1973-11-27
- Latest
- 2026-05-07
- Applications
- 7